Chris Spooner

Chris Spooner is an experienced executive in the aesthetics industry who served as the CEO of Sinclair Pharma, a global aesthetics company headquartered in London.1 He was appointed CEO of Sinclair Pharma in December 2009 and led the company for over 12 years.2

Career Highlights

During his tenure at Sinclair Pharma, Spooner played a crucial role in transforming the company:

• He oversaw the transformation of Sinclair from a small, unprofitable medicinal dermatology company into a major player in the aesthetic market.13
• Under his leadership, Sinclair was acquired by Huadong Medicine Company Limited in 2018 and continued its rapid growth.1

Background and Experience

Before joining Sinclair Pharma, Chris Spooner had a diverse background in the life sciences and financial sectors:

• He has 15 years of experience analyzing and investing in life science companies.2
• Spooner worked as a top-rated pharmaceuticals analyst at various investment banks, including JP Morgan, Deutsche Bank, Donaldson Lufkin & Jenrette, and Bank of America.2
• Prior to Sinclair, he was the founding partner and CEO of HealthCor Management UK LLP, the European division of HealthCor LP, a leading New York-based specialist healthcare fund.25

Education

Chris Spooner holds an MA in Economics from King's College, Cambridge.24

Recent Developments

In May 2022, it was announced that Chris Spooner would be stepping down as CEO of Sinclair Pharma, to be replaced by Miguel Pardos.1 Following this transition, Spooner took on a consultancy role with the company.1